Brady Releases Labeling System Designed for Labs
Brady introduces Labxpert v2.0 model to fulfill labeling requirements of the lab.
Oxfordshire, UK-May 13, 2008-Brady's (www.bradylab.co.uk) Labxpert™ labeling system was specifically designed for the labeling requirements of the modern laboratory and is capable of producing clear, permanent labels for virtually any laboratory application-flasks, tubes, straws, microplates and microscope slides, to name only a few.
The Labxpert’s 300dpi resolution printing means that even the smallest fonts and barcodes can be printed with complete clarity and legibility. More than 140 lab-specific symbols (Greek, scientific, and safety symbols) are instantly available for added convenience. This compact, lightweight (less than 1Kg), hand-held device can produce labels 80% faster than hand-writing-and with font sizes down to 1mm, far more information can be included than on any hand-written label. The innovative “Drop, Lock, and Print” Smart Cartridge makes it quick and easy to change between different labeling jobs.
However, Brady points out that in laboratory labeling the printer, however good, is only part of the story. It is when the Labxpert is combined with the unique range of specialized label materials and print media available from Brady that a solution will be found for virtually any laboratory labeling task. Labels can be produced that will withstand the harshest environments-temperatures from liquid nitrogen (-196°C) to autoclave (+121°C), and solvents like Xylene, Ethanol, DMSO, and IPA-and that will remain intact and legible through many cycles of immersion and repeated handling. Brady Freezerbondz II labels can even be applied to already frozen surfaces.
According to Brady, the latest Labxpert v2.0 model has a USB port for easy PC connectivity, plus narrower bar codes and 10 new font sizes to fit more information on the very small labels needed for some laboratory consumables. The optional IdentiLab™ PC software has easy-to-use wizards for label creation and tools for more advanced applications such as database import, automatic text formatting, multi-label data entry, and 2-D bar codes.
Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
May 2nd 2025Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly semaglutide improved liver histology, metabolic markers, and weight loss in patients with biopsy-confirmed metabolic dysfunction–associated steatohepatitis and stage 2 or 3 fibrosis.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
